What is Omeza?
Omeza operates at the intersection of biotechnology and advanced wound care, focusing on the development of provider-administered therapies that address the physiological complexities of hard-to-heal wounds. Unlike digital health platforms, Omeza prioritizes the physical restoration of skin integrity through innovative therapeutic agents that manage inflammation and promote cellular repair. Its market position is defined by a commitment to evidence-based clinical outcomes, targeting a significant unmet need in the healthcare sector for effective, non-surgical interventions for patients suffering from chronic skin conditions. By streamlining the healing process, the company provides a scalable alternative to traditional wound management protocols.
How much funding has Omeza raised?
Omeza has raised a total of $15.8M across 4 funding rounds:
Seed
$7M
Debt
$150K
Debt
$180K
Series A
$8.5M
Seed (2019): $7M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Debt (2021): $180K supported by PPP
Series A (2026): $8.5M featuring BluKap, Catalyst Fund, Florida Opportunity Fund, and Astanor Ventures
Key Investors in Omeza
BluKap
BluKap is a venture capital firm focused on driving innovation in the ocean economy through investments in late seed stages and Series A companies.
Catalyst Fund
Catalyst Investments is a prominent Israeli multi-fund firm specializing in investment and value creation for technology companies at various stages of development.
Florida Opportunity Fund
Florida Opportunity Fund is dedicated to investing in early-stage companies to enhance Florida's innovation economy across life sciences and technology.
What's next for Omeza?
With the successful closure of this Series A round, Omeza is positioned to accelerate its clinical development pipeline and expand its market reach. The strategic capital will likely be deployed to scale manufacturing capabilities and broaden the distribution of its regenerative products to healthcare providers globally. As the company enters this growth phase, the focus will shift toward securing broader clinical adoption and validating the long-term efficacy of its therapeutic portfolio. The involvement of specialized venture capital partners suggests a clear roadmap toward establishing Omeza as a leader in the regenerative medicine space, with an emphasis on sustainable growth and long-term value creation in the medical technology sector.
See full Omeza company page
